MOUNTAIN VIEW, Calif.,
Oct 21 /PRNewswire-FirstCall/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the
appointment of Thomas P. McCracken
as Vice President, Intellectual Property. Mr. McCracken will lead
the company's intellectual property program in support of the
potential commercialization of the company's lead product
candidate, LEVADEX™ orally inhaled migraine therapy, and other
product opportunities.
Mr. McCracken has extensive legal experience within the
healthcare industry. Most recently, Mr. McCracken was Vice
President and Chief Patent Counsel at Durect Corporation, where he
was responsible for management, development and creation of all
intellectual property assets. He was previously with
PowderJect Pharmaceuticals, where he was responsible for managing
IP assets and services across all research and development
functions of the company, including vaccines, biopharmaceuticals
and medical devices. Prior to PowderJect, Mr. McCracken was
in private patent law practice and specialized in the areas of
pharmaceuticals, biotechnology, biomedical engineering and medical
devices. His knowledge of the biotechnology field is further
supplemented with several years of technical experience in research
and development at privately held biopharmaceutical companies,
including research activities at the Research Institute of Scripps
Clinic.
"Tom joins the company at an ideal time, as his expertise in
patent and trademark planning, patent claims structuring and
technology licensing will benefit us as we prepare for the
potential commercialization of LEVADEX and develop other potential
pipeline products," said Timothy S.
Nelson, President and Chief Executive Officer of MAP
Pharmaceuticals.
Mr. McCracken holds a Bachelor's degree in Microbiology from the
University of California, San Diego and
a Juris Doctor degree from Santa Clara
University School of Law. He is registered to practice
with the U.S. Patent and Trademark Office and is a member of the
State Bar of California.
About MAP Pharmaceuticals
MAP Pharmaceuticals is dedicated to developing and
commercializing new therapies for patients suffering from
conditions that are not adequately treated by currently available
medicines. The company is developing LEVADEX orally inhaled therapy
for the potential treatment of migraine and has reported positive
results from the efficacy portion of its Phase 3 trial of LEVADEX.
In addition, MAP Pharmaceuticals generates new pipeline
opportunities by applying its proprietary drug particle and
inhalation technologies to enhance the therapeutic benefits of
proven drugs, while minimizing risk by capitalizing on their known
safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
Forward-Looking Statements
In addition to statements of historical facts or statements of
current conditions, this press release contains forward-looking
statements, including with respect to MAP Pharmaceuticals' LEVADEX
product candidate. Actual results may differ materially from
current expectations based on risks and uncertainties affecting the
Company's business, including, without limitation, risks and
uncertainties relating the conduct and completion of clinical
trials, and relating to the preparation and filing of a New Drug
Application and the regulatory process to have the Company's
LEVADEX product candidate approved for commercial use. The reader
is cautioned not to unduly rely on the forward-looking statements
contained in this press release. MAP Pharmaceuticals expressly
disclaims any intent or obligation to update these forward-looking
statements, except as required by law. Additional information on
potential factors that could affect MAP Pharmaceuticals' results
and other risks and uncertainties are detailed in its Quarterly
Report on Form 10-Q for the quarter ended June 30, 2010, available at
http://edgar.sec.gov.
CONTACTS:
|
|
|
|
Nicole Foderaro
|
|
|
WCG
|
|
|
(415) 946-1058
|
|
|
nfoderaro@wcgworld.com
|
|
|
|
SOURCE MAP Pharmaceuticals, Inc.